UNSPSC 51391721: Fenoterol

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C17H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22M9P70OQ9, chemically known as 3,5-dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol but generally known as fenoterol, which bears US NIH Compound Identifier 3343. European Medicines Agency schedules Fenoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07579MIG.

UNSPSC 51391721 Fenoterol is a Commodity code that in practice captures state and local procurement of pharmaceutical products and related medical supplies, though recent activity under this code shows a significant mismatch between the code's nominal scope and the work actually being solicited. The most recent solicitations tagged to this code involve naloxone acquisition and pharmaceutical supply-chain management rather than fenoterol specifically. State and local governments use this code family to buy pharmaceutical inventory, medical countermeasures, and related health services through competitive bidding processes. Issuing bodies include county health departments and state health and human services agencies pursuing community health initiatives and pharmacy benefit programs.

Seminole County, Florida posted an IFB on June 30, 2026 (response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the county required electronic bid submission through its e-Procurement Portal with inclusive shipping costs and offered an initial two-year contract term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for establishing state pharmacy benefit relationships outside traditional pharmacy benefit manager and group purchasing organization arrangements. Recent activity concentrates in Florida and Texas, with both solicitations reflecting state and local emphasis on pharmaceutical supply security, cost management, and direct-vendor relationships.